<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2021">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341610</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2020-001330-36</org_study_id>
    <nct_id>NCT04341610</nct_id>
  </id_info>
  <brief_title>ASC Therapy for Patients With Severe Respiratory COVID-19</brief_title>
  <acronym>ASC COVID-19</acronym>
  <official_title>Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emerging field of stem cell therapy holds promise of treating a variety of diseases.&#xD;
      Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have&#xD;
      proven their potential for regenerative therapy in patients with ischemic heart disease. Both&#xD;
      of these cell types have putative immunomodulatory properties, as they have demonstrated&#xD;
      their ability to evade recognition and actively suppress the immune system.&#xD;
&#xD;
      This knowledge is transferred into studies with COVID-19 patients having severe pulmonary&#xD;
      dysfunction, to modify the virus induced immunological and inflammatory activity involved in&#xD;
      the progression of disease often leading to prolonged ICU stay and in some occasion's death.&#xD;
&#xD;
      We will conduct a clinical trial in which patients with COVID-19 and severe pulmonary&#xD;
      symptoms will be randomized to either placebo or treatment with allogeneic CSCC_ASCs from&#xD;
      adipose tissue. The aim is to assess the impact of CSCC_ASCs on the activated immune system&#xD;
      and clinical efficacy on pulmonary function.&#xD;
&#xD;
      The perspective is that this new information can be of pivotal importance and potentially be&#xD;
      a paradigm shift for the clinical problems and severe outcome seen in some patients with&#xD;
      severe COVID-19 and other severe diseases with Acute Respiratory Distress Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not approved by ethical committee&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in clinical critical treatment index</measure>
    <time_frame>day 7 from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of respirator treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of clinical symptoms including duration of fever and respiratory need</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marker of Immunological function -CD4+ and CD8+ T cell count</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein and leucocyte</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 million allogeneic adipose-derived mesenchymal stromal cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stem Cell Product</intervention_name>
    <description>100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline</description>
    <arm_group_label>ASC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18-80 years&#xD;
&#xD;
          -  Confirmed HCoV-19 infection&#xD;
&#xD;
          -  Temperature above 38.0o C&#xD;
&#xD;
          -  Pulmonary symptoms and signs, at least one of the following before clinical decision&#xD;
             for intubation and respirator treatment:&#xD;
&#xD;
               1. Respiratory distress, RR ≥ 30/min;&#xD;
&#xD;
               2. Oxygen saturation ≤ 93% at rest state;&#xD;
&#xD;
               3. Arterial partial pressure of oxygen (PaO2) / Fraction of inspiration O2 (FiO2) ≤&#xD;
                  300mmHg, 1mmHg=0.133kPa&#xD;
&#xD;
          -  Pneumonia that is judged by chest radiograph or computed tomography&#xD;
&#xD;
          -  In respirator and possible for treatment within the first 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that have need for additional immunosuppressive treatment&#xD;
&#xD;
          -  Patients with any past (within the past 3-5 years) or present malignancy (other than&#xD;
             excised basal cell carcinoma).&#xD;
&#xD;
          -  Co-Infection with other infectious agent.&#xD;
&#xD;
          -  Females capable of becoming pregnant must have a negative pregnancy test prior to&#xD;
             treatment. After inclusion, they must use contraceptives for 2 months following the&#xD;
             given stem cell treatment. The pill, spiral, depot injection of progesterone,&#xD;
             sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe&#xD;
             contraceptives.&#xD;
&#xD;
          -  Patients who are participating in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>JKastrup</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

